ABL1 is altered in 0.52% of Ewing sarcoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is altered in 0.67% of Ewing sarcoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

AXL is altered in 0.66% of Ewing sarcoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is altered in 3.12% of Ewing sarcoma patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA1 is altered in 0.65% of Ewing sarcoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 1.91% of Ewing sarcoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is altered in 0.68% of Ewing sarcoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is altered in 0.66% of Ewing sarcoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is altered in 0.69% of Ewing sarcoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EWSR1 is altered in 89.04% of Ewing sarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 8 clinical trials for Ewing sarcoma, of which 7 are open and 1 is closed. Of the trials that contain EWSR1 status and Ewing sarcoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCA is altered in 0.67% of Ewing sarcoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is altered in 1.33% of Ewing sarcoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is altered in 2.56% of Ewing sarcoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is altered in 2.08% of Ewing sarcoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is altered in 1.96% of Ewing sarcoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is altered in 13.33% of Ewing sarcoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLI1 is altered in 73.33% of Ewing sarcoma patients [2].

FLI1 is an inclusion eligibility criterion in 3 clinical trials for Ewing sarcoma, of which 3 are open and 0 are closed. Of the trials that contain FLI1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FUS is altered in 0.75% of Ewing sarcoma patients [2].

FUS is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FUS status and Ewing sarcoma as inclusion criteria, 2 are phase 1 (2 open) [3].

KMT2A is altered in 0.66% of Ewing sarcoma patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is altered in 1.03% of Ewing sarcoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is altered in 2.78% of Ewing sarcoma patients [2].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MRE11A is altered in 0.78% of Ewing sarcoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is altered in 1.26% of Ewing sarcoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and Ewing sarcoma as inclusion criteria, 1 is no phase specified (1 open) [3].

NBN is altered in 0.68% of Ewing sarcoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PALB2 is altered in 0.66% of Ewing sarcoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 0.51% of Ewing sarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 1.54% of Ewing sarcoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is altered in 1.54% of Ewing sarcoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPTOR is altered in 1.54% of Ewing sarcoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is altered in 2.86% of Ewing sarcoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TAF15 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TAF15 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 13.33% of Ewing sarcoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TSC1 is altered in 1.25% of Ewing sarcoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 0.62% of Ewing sarcoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].